Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OC101
- Development stage
- Preclinical
- Lead developer
- Oncocross
- Modality
- Small Molecules
01
Overview
OC101 is an AI-discovered drug candidate being developed by Oncocross for the treatment of liver disorders, including liver cirrhosis and nonalcoholic steatohepatitis (NASH). Identified using the company's proprietary RAPTOR AI platform, OC101 is classified as an incrementally modified drug (IMD), a regulatory category often used for drugs with improved formulations, structures, or new indications based on existing compounds. The drug is currently in the IND-enabling (in vivo) stage of development. While its specific molecular target and active ingredient remain proprietary, it is designed to address the underlying pathology of liver fibrosis and cirrhosis.
Beyond the preview
Go deeper on OC101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OC101.